Karl Hård
Investor Relations Contact at EGETIS THERAPEUTICS AB
Profile
Karl J.
Hård is currently the VP, Head-Investor Relations & Communications at Egetis Therapeutics AB.
Previously, he worked as an Investor Relations Contact at AstraZeneca PLC and as an Assistant Professor at the University of Leiden.
He also served as the Head-Investor Relations & Corporate Communications at Redx Pharma Plc from 2016 to 2017 and as the Head-Investor Relations & Communications at Kiadis Pharma NV from 2017 to 2018.
Dr. Hård holds a doctorate degree from the University of Utrecht and a graduate degree from the University of Helsinki.
Karl Hård active positions
| Companies | Position | Start |
|---|---|---|
| EGETIS THERAPEUTICS AB | Investor Relations Contact | 01/02/2022 |
Former positions of Karl Hård
| Companies | Position | End |
|---|---|---|
| KIADIS PHARMA N.V. | Investor Relations Contact | 31/12/2018 |
| REDX PHARMA PLC | Investor Relations Contact | 02/07/2017 |
| University of Leiden | Corporate Officer/Principal | - |
| ASTRAZENECA PLC | Public Communications Contact | - |
Training of Karl Hård
| University of Utrecht | Doctorate Degree |
| University of Helsinki | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| EGETIS THERAPEUTICS AB | Health Technology |
| REDX PHARMA PLC | Health Technology |
| Private companies | 1 |
|---|---|
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Karl Hård